Clinical trial results:
3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals

Summary

EudraCT number	2012-005636-29
Trial protocol	BG
Global end of trial date	20 March 2015

Results information

Result version number	v1 (current)
This version publication date	31 March 2016
First version publication date	31 March 2016

Trial information

Trial identification

Sponsor protocol code	MK-1894-009

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01721265
WHO universal trial number (UTN)	-
Other trial identifiers	Idenix Protocol Number: IDX-03YF

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 March 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	20 March 2015
Global end of trial reached?	Yes
Global end of trial date	20 March 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

All participants in this study have previously been in an Idenix hepatitis C virus (HCV) study and received study drug for 3 consecutive days. Participants who had received placebo in a previous Idenix study will not be enrolled in this study.

In this study, researchers will try to find answers to these questions:
•How much (if any) HCV is in your blood after stopping your Idenix study drug?
•Is your HCV possibly resistant to treatment with the Idenix study drug or similar drugs?

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 September 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Israel: 6
Country: Number of subjects enrolled	United States: 138
Worldwide total number of subjects	145
EEA total number of subjects	1

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	138
From 65 to 84 years	7
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Adult male and female participants who participated in an Idenix study and received ≥3 doses of a direct-acting antiviral (DAA) were recruited for this 3-year observational follow-up study.

Pre-assignment

Screening details:

A total of 145 participants were drawn from Idenix studies IDX-06A-001 (n=17), IDX-06A-005 (n=78), IDX-08C-004 (n=16), and IDX-08C-005 (n=34).

Period 1

Period 1 title	3-Year Observational Period (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

This was an unblinded observational follow-up study.

Arms

Arm title	Prior Idenix DAA Treatment

Arm description:

Adult male and female participants who had previously participated in an Idenix HCV study in which they had previously received ≥3 doses of a DAA.

Arm type	Experimental
Investigational medicinal product name	MK-2355
Investigational medicinal product code	
Other name	IDX184
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants who took ≥3 consecutive daily doses of MK-2355 in an earlier study were followed in the current study.

Investigational medicinal product name	MK-1894
Investigational medicinal product code	
Other name	IDX719
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Participants who took ≥3 consecutive daily doses of MK-1894 in an earlier study were followed in the current study.

Number of subjects in period 1	Prior Idenix DAA Treatment
Started	145
Completed	0
Not completed	145
Consent withdrawn by subject	12
Active at time of study discontinuation	126

Lost to follow-up	4
Initiated other treatment	3

Baseline characteristics

Reporting groups	
Reporting group title	Prior Idenix DAA Treatment

Reporting group description:

Adult male and female participants who had previously participated in an Idenix HCV study in which they had previously received ≥3 doses of a DAA.

Reporting group values	Prior Idenix DAA Treatment	Total	
Number of subjects	145	145	
Age Categorical Units: Subjects			
Adults (18-64 years)	138	138	
Adults (65 to 84 years)	7	7	
Age Continuous Units: years			
arithmetic mean	51.4		
standard deviation	± 10.5	-	
Gender Categorical Units: Subjects			
Female	70	70	
Male	75	75	

End points

End points reporting groups

Reporting group title	Prior Idenix DAA Treatment

Reporting group description:

Adult male and female participants who had previously participated in an Idenix HCV study in which they had previously received ≥3 doses of a DAA.

Primary: Number of participants with HCV RNA <LLoQ

End point title	Number of participants with HCV RNA <LLoQ[1]

End point description:

The number of participants with HCV ribonucleic acid (RNA) below the lower limit of quantification (LLoQ) at consecutive 3-month intervals after prior IDX DAA treatment was determined. Plasma HCV RNA was assessed using the Roche COBAS Taqman 96 assay v.2.0, which has a LLoQ of 15 IU/mL.

End point type	Primary

End point timeframe:

Months 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Per protocol, only descriptive statistics were presented.

End point values	Prior Idenix DAA Treatment			
Subject group type	Reporting group			
Number of subjects analysed	144			
Units: Number of participants				
Month 0 (n=144)	81			
Month 3 (n=134)	73			
Month 6 (n=115)	61			
Month 9 (n=94)	44			
Month 12 (n=62)	24			
Month 15 (n=46)	17			
Month 18 (n=45)	15			
Month 21 (n=32)	8			
Month 24 (n=27)	6			
Month 27 (n=13)	2			
Month 30 (n=1)	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Kinetics of resistance associated variants (RAVs)

End point title	Kinetics of resistance associated variants (RAVs)

End point description:

The kinetics of RAVs to IDX DAAs in participants who were virologic failures in the initial studies, or had relapsed in this study, were to be analyzed. However, analysis of RAVs was not performed due to early

termination of this study.

End point type	Secondary

End point timeframe:

Months 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30

End point values	Prior Idenix DAA Treatment			
Subject group type	Reporting group			
Number of subjects analysed	0[2]			
Units: RAVs				

Notes:

[2] - Analysis of RAVs was not performed due to early study termination.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events: Safety data (including adverse events) were not collected and therefore no analysis was planned.	
Assessment type	Non-systematic

Dictionary used	
Dictionary name	Not applicable
Dictionary version	N/A

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: Safety data (including adverse events) were not collected and therefore no analysis was planned.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
19 March 2015	The integration of Idenix compounds into the Merck HCV antiviral pipeline resulted in revisions to the clinical development plan. Merck discontinued development of IDX18719 (MK-1894) and Idenix had discontinued IDX14184 (MK-2355) prior to acquisition. Consequently, the IDX-03YF study involving these two compounds was terminated early.	-

Notes:

Limitations and caveats

None reported